Literature DB >> 30129899

Baseline Volumetric Multiparametric MRI: Can It Be Used to Predict Survival in Patients with Unresectable Intrahepatic Cholangiocarcinoma Undergoing Transcatheter Arterial Chemoembolization?

Ankur Pandey1, Pallavi Pandey1, Mounes Aliyari Ghasabeh1, Manijeh Zarghampour1, Pegah Khoshpouri1, Sanaz Ameli1, Yan Luo1, Ihab R Kamel1.   

Abstract

Purpose To evaluate whether baseline MRI can help predict survival in patients with unresectable intrahepatic cholangiocarcinoma (ICCA) undergoing transcatheter arterial chemoembolization (TACE). Materials and Methods This retrospective study was compliant with HIPAA and approved by the institutional review board. The requirement to obtain informed consent was waived. The study included 111 patients (mean age, 62 years ± 12; range, 29-86 years), with 44 men (mean age, 61 years ± 12; range, 29-81 years) and 67 women (mean age, 63 years ± 12; range, 34-86 years). Patients underwent TACE after baseline MRI, which included contrast-enhanced and diffusion-weighted imaging with apparent diffusion coefficient (ADC) mapping between 2003 and 2016. The single largest tumor was assessed independently by a radiologist for anatomic and functional (viable tumor volume, percentage viable tumor volume [100 × viable tumor volume/whole tumor volume], viable tumor burden [100 × viable tumor volume/whole liver volume], and ADC) parameters. Survival analysis was performed with Kaplan-Meier and Cox regression analysis. Results Overall survival (OS) was higher with a baseline ADC of 1415 × 10-6 mm2/sec or less compared with greater than 1415 × 10-6 mm2/sec (P = .005; 25th percentile of OS, 17 months vs 7 months, respectively), percentage viable tumor volume greater than 90% compared with 90% or less (P = .001; 25th percentile of OS, 20 months vs 7 months, respectively), and viable tumor burden greater than 6.6% compared with 6.6% or less (P = .09; 25th percentile of OS, 17 months vs 7 months, respectively). Baseline ADC greater than 1415 × 10-6 mm2/sec (hazard ratio [HR]: 2.176 [95% confidence interval: 1.217, 3.891]; P = .009) and percentage viable tumor volume greater than 90% (HR: 0.319 [95% confidence interval: 0.148, 0.685]; P = .003) were associated with OS independent of clinical confounders (age and sex). At multiparametric MRI risk stratification (with low ADC and high percentage viable tumor volume considered favorable for survival), differences in OS were noted (P = .002; 25th percentile of OS for low vs intermediate vs high risk, 22 months vs 10 months vs 7 months, respectively). Conclusion Baseline multiparametric MRI assessment including volumetric ADC, percentage viable tumor volume, and viable tumor burden can help predict mortality risk among patients with intrahepatic cholangiocarcinoma undergoing transcatheter arterial chemoembolization. © RSNA, 2018 Online supplemental material is available for this article.

Entities:  

Mesh:

Year:  2018        PMID: 30129899     DOI: 10.1148/radiol.2018180450

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  3 in total

1.  Prognostic value of baseline volumetric multiparametric MR imaging in neuroendocrine liver metastases treated with transarterial chemoembolization.

Authors:  Yan Luo; Ankur Pandey; Mounes Aliyari Ghasabeh; Pallavi Pandey; Farnaz Najmi Varzaneh; Manijeh Zarghampour; Pegah Khoshpouri; Sanaz Ameli; Zhen Li; Daoyu Hu; Ihab R Kamel
Journal:  Eur Radiol       Date:  2019-03-15       Impact factor: 5.315

2.  Role of 3D quantitative tumor analysis for predicting overall survival after conventional chemoembolization of intrahepatic cholangiocarcinoma.

Authors:  Irvin Rexha; Fabian Laage-Gaupp; Julius Chapiro; Milena Anna Miszczuk; Johanna Maria Mijntje van Breugel; MingDe Lin; Menelaos Konstantinidis; Rafael Duran; Bernhard Gebauer; Christos Georgiades; Kelvin Hong; Nariman Nezami
Journal:  Sci Rep       Date:  2021-04-29       Impact factor: 4.379

3.  DWI-based radiomic signature: potential role for individualized adjuvant chemotherapy in intrahepatic cholangiocarcinoma after partial hepatectomy.

Authors:  Dong Kuang; Xuemei Hu; Yang Yang; Xianlun Zou; Wei Zhou; Guanjie Yuan; Daoyu Hu; Yaqi Shen; Qingguo Xie; Qingpeng Zhang; Zhen Li
Journal:  Insights Imaging       Date:  2022-03-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.